Dr. Adam Davenport joins Dalriada Drug Discovery as Chief R&D Officer TORONTO, May 03, 2023 (GLOBE NEWSWIRE) — Dalriada, a leading Canadian contract research organization specializing in small molecule therapies, announces today that it has strengthened its executive leadership team, appointing Adam Davenport, Ph.D. as its Chief Research & Development…Read More
Dalriada brings in former Evotec executive Adam Davenport to lead strategy execution as Chief RD Officer
